Bafna Pharmaceuticals, a well-known manufacturer and exporter of drug formulations, expects a three-fold jump in its revenue on the back of its entry into the US market.

The company is hopeful to achieve revenue of Rs 125 crore in the next financial year as compared to present Rs 40 crore.

Currently, the Chennai-based pharmaceutical company is in the process of filing ANDAs (abbreviated new drug applications) in the US for anti-retro viral drugs for AIDS. The ANDA is likely to get approval in 18 months.

The company's net profit for September 2009 has increased by 5.23 times amounting to Rs 1.23 crere compare to loss of Rs 23 lakh in corresponding previous quarter of last year.